Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-19T10:31:52.278Z Has data issue: false hasContentIssue false
  • English
  • Français

Right Idea, Wrong Result—Canada's Access to Medicines Regime

Published online by Cambridge University Press:  06 January 2021

Paige E. Goodwin
Paige E. Goodwin*
Affiliation:
Boston University School of Law, Dalhousie University
Get access Rights & Permissions [Opens in a new window]

Extract

In 2007, an estimated 33.2 million people were living with HIV, 2.5 million had become infected, and 2.1 million died from the virus. The majority of infected individuals reside in Africa, where in some countries as many as 33.4% of adults have HIV. In developed countries, effective drug therapies have reduced AIDS-related deaths by over seventy percent each year. These drugs have been so effective that over the last two years the global number of individuals dying from AIDS-related illness has actually declined. These therapies, however, are currently sold for $10,000 USD a year, a purchase price that is not feasible for low income countries where the annual health expenditure may be only $29 per person. A lack of essential medicine is not only a problem for those suffering from AIDS. Low and middle-income countries are disproportionately burdened by many additional chronic and infectious illnesses. The World Health Organization (“WHO”) estimates that one third of the world's population cannot regularly access essential medicines. The WHO cites the high cost of drugs as one of the major hurdles countries face in obtaining access to medication. However, the high cost of these brand-name medications does not reflect their minimal production costs. Drug manufacturers can produce generic versions of these drugs for as little as 1/30th of the cost of their brand-name counterparts.

Type
Article
Information
American Journal of Law & Medicine , Volume 34 , Issue 4 , December 2008 , pp. 567 - 584
Copyright
Copyright © American Society of Law, Medicine and Ethics and Boston University 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Press Release, UNAIDS, Global HIV Prevalence Has Leveled Off; AIDS Is Among the Leading Causes of Death Globally and Remains the Primary Cause of Death in Africa (Nov. 20, 1997), available at http://data.unaids.org/pub/EPISlides/2007/071119_epi_pressrelease_en.pdf [hereinafter UNAIDS Press Release].

2 UNAIDS, Report on the Global AIDS Epidemic 6 (2006), http://data.unaids.org/pub/GlobalReport/2006/2006_GR-ExecutiveSummary_en.pdf.

3 Canadian HIV/AIDS Legal Network, The Jean Chrétien Pledge to Africa Act and its Impact on Improving Access to HIV/AIDS Treatment in Developing Countries 1 (2007), http://www.aidslaw.ca/publications/interfaces/downloadFile.php?ref=696.

4 UNAIDS Press Release, supra note 1, at 2.

5 Outterson, Kevin, Patent Buy-Outs for Global Disease Innovations for Low- and Middle-Income Countries, 32 Am. J. L. & Med. 159, 160 (2006)CrossRefGoogle ScholarPubMed.

6 Id. at 168.

7 Id. at 160.

8 U.S. Gov’t. Accountability Office, GAO-07-1198, Intellectual Property: U.S. Trade Policy Guidance on WTO Declaration on Access to Medicines May Need Clarification 13 (2007).

9 Id.

10 Outterson, Kevin, Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets, 5 Yale J. Health Pol'y L. & Ethics 193, 253 (2005)Google ScholarPubMed.

11 Id.

12 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, 33 I.L.M. 81 (1994), available at http://www.wto.org/english/docs_e/legal_e/27-trips.pdf [hereinafter TRIPS].

13 Rogers, Jennifer May, The TRIPS Council's Solution to the Paragraph 6 Problem: Toward Compulsory Licensing Viability for Developing Countries, 13 Minn. J. Global Trade 443, 443-44 (2004)Google Scholar.

14 TRIPS, supra note 12, at art. 31 (“This requirement may be waived by a Member in the case of a national emergency or other circumstances of extreme urgency or in cases of public noncommercial use.”).

15 Id. at art. 31.

16 Fayerman, Jessica J., The Spirit of TRPS and the Importation of Medicines Made Under Compulsory License After the August 2003 TRIPS Council Agreement, 25 Nw. J. Int’l L. & Bus. 257, 261 (2004)Google Scholar.

17 TRIPS, supra note 12, at art. 27.

18 Rogers, supra note 13, at 449.

19 Jessica J. Fayerman, supra note 16, at 257, 262.

20 Shumani Gereda, The Aftermath of Canada's Implementation of the Doha Declaration on the Future of Pharmaceutical Innovation 33 (Soc. Sci. Res. Network, Working Paper 1099383, 2008), http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1099383.

21 Fayerman, supra note 16, at 257, 262.

22 Condon, Bradly & Sinha, Tapen, Global Diseases, Global Patents and Differential Treatment in WTO Law: Criteria for Suspending Patent Obligations in Developing Countries 26 Nw. J. Int’l L. & Bus. 1, 10 (2005)Google Scholar.

23 Id.

24 Id. at 11.

25 Gereda, supra note 20, at 37.

26 Penner, Mark D. & Narayanan, Prakash, Amendments to the Canadian Patent Act to Address Drug Access: Is Help on the Way? 60 Food & Drug L.J. 459 (2005).Google Scholar

27 Government of Canada, Report on the Statutory Review of Sections 21.01 to 21.19 of the Patent Act 1 (2007) http://camr-rcam.hc-sc.gc.ca/index_e.html.

28 Canada Grants Waiver for Rwanda AIDS Drug, Reuters, Oct 5, 2007, available at http://www.reuters.com/article/health-SP/idUSL0521156720071005.

29 Cohen-Kohler, Jillian C, Esmail, Laura C & Cosio, Andrea Perez, Canada's Implementation of the Paragraph 6 Decision: Is It Sustainable Public Policy? 3:12 Globalization & Health (2007)CrossRefGoogle ScholarPubMed, http://www.globalizationandhealth.com/content/3/1/12; see also Letter from Marcelo Vizio, General Manager, Abbott Laboratories to Douglas Clark, Director, Patent Policy Directoraté & Brigitte Zirger, Director, Therapeutic Products Directoraté (Jan. 24, 2007), available at http://camr-rcam.hc-sc.gc.ca/reviewreviser/index_e.html.

30 U.S. Government Accountability Office, GAO-07-1198, Intellectual Property: U.S. Trade Policy Guidance on WTO Declaration on Access to Medicines May Need Clarification 8 (2007)Google Scholar.

31 Id.

32 Whorbrey, Brittany, International Patent Law and Public Health: Analyzing TRIPS’ Effect on Access to Pharmaceuticals in Developing Countries, 45 Brandeis L.J. 623, 630 (2007)Google Scholar.

33 TRIPS, supra note 12, at art. 27(1).

34 Id. at art. 28(1).

35 Id.

36 Id. at art. 31.

37 Id. at art. 31(b).

38 Id.

39 Id. at art. 31(c).

40 Id. at art. 31(d)-(f).

41 Id. at art. 31(g).

42 Id. at art. 31(h).

43 Whorbrey, supra note 32, at 635.

44 Fayerman, supra note 16, at 261.

45 Id. at 262 (citing Doha Declaration infra note 46).

46 Gereda, supra note 20, at 33.

47 Rogers, supra note 13, at 449.

48 World Trade Organization, Ministerial Declaration of 14 November 2001, WT/MIN(01)/DEC 1, 41 I.L.M. 746 ¶¶4, 6 (2001), http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.pdf [hereinafter Doha Declaration].

49 Fayerman, supra note 16, at 262-63.

50 Decision of the General Council, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health¶2, WT/L/540 (Aug. 30, 2003), available at http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm [hereinafter Decision of the WTO General Council].

51 Id. at ¶2(a)(i)-(iii).

52 Id. at ¶2(b)(i)-(ii).

53 Id. at ¶3.

54 Id. at ¶4.

55 Canadian HIV/AIDS Legal Network, supra note 3, at 3.

56 Id.

57 Id. at 4.

58 CAMR is an amendment to Canada's Patent Act. It can be located at The Patent Act, 2004 S.C., ch. 23, § 21.04(1), available at http://www.canlii.org///ca/as/2004/c23/sec1.html [hereinafter CAMR].

59 Id. at § 21.11.

60 Id. at § 21.1.

61 Id. at § 21.09.

62 Id. at § 21.12.

63 Id. at § 21.04(2).

64 Id. at § 21.04(3)(b).

65 Id. at § 21.04(3)(c).

66 Id. at § 21.04(3).

67 Id. at § 21.06.

68 Id. at § 21.06.

69 Id. at § 21.08(1).

70 Id. at § 21.08(2).

71 Canadian HIV/AIDS Legal Network, supra note 3, at 5.

72 Id. at 4.

73 CAMR, supra note 58, at § 21.08(4).

74 Id. at § 21.14.

75 Id. at sched. 1.

76 Decision of the WTO General Council, supra note 50, at ¶1.

77 CAMR, supra note 58, at § 21.03(1)(a)(i).

78 Penner & Narayanan, supra note 26, at 462.

79 Id.

80 Id. at 462-63.

81 Rwanda First to Try Buying Affordable AIDS Drugs from Canada Using Access to Medicines Regime, Canada News Wire, July 20, 2007, http://www.bcpwa.org/articles/HIVAIDS_NEWS_Aug092007.doc#_Article_2_wanda (last visited Oct. 30, 2008).

82 Alexander G. Higgins, Canada Says Rwanda Will get AIDS Drugs, Forbes.com, Oct. 5, 2008, http://www.forbes.com/feeds/ap/2007/10/05/ap4192362.html.

83 Tanya Talaga, AIDS Drug Fiasco a Tale of Red Tape, thestar.com, Aug. 9, 2007, http://www.thestar.com/article/244582.

84 Higgins, supra note 82.

85 Press Release, Apotex Inc, Life Saving AIDS Drug for Africa Gets Final Clearance (Sept. 20, 2007), http://www.apotex.com/PressReleases/20070920-01.asp.

86 Id.

87 Talaga, supra note 84.

88 Elliot, Richard, Delivery Past Due: Global Precedent Set Under Canada's Access to Medicines Regime, 13(1) HIV/AIDS Pol’y & L. Rev. 1, 6 (2008)Google Scholar, available at http://www.aidslaw.ca/publications/interfaces/downloadFile.php?ref=1345.

89 Talaga, supra note 83.

90 Id.

91 Gereda, supra note 20, at 25.

92 Id.

93 Id. at 26.

94 Id.

95 Outterson, Patent Buy Outs, supra note 5, at 160.

96 Id. at 164.

97 Outterson, Pharmaceutical Arbitrage, supra note 10, at 223.

98 Id. at 262.

99 Id.

100 Id. at 265-67.

101 See, e.g., CAMR, supra note 58, at § 21.06.

102 The Human Rights Working Group on HIV/AIDS and Public Health, Canada's Access to Medicines Regime (CAMR) Consultation Submission 5 (2007)Google Scholar.

103 CAMR, supra note 58, at § 21.04(3)(b).

104 Letter from John Hems, Director, Regulatory Affairs, Apotex Inc., to Douglas Clark, Director, Patent Policy Directorate, Industry Canada 3 (Jan. 23, 2007), http://camr-rcam.hcsc.gc.ca/review-reviser/camr_rcam_apotex_18-eng.pdf [hereinafter Apotex Letter].

105 Elliot, supra note 88, at 1.

106 Letter from Chris Halyk, President, Janssen-Ortho, Inc., to Douglas Clark, Director, Patent Policy Directorate, Industry Canada 1-2 (Jan. 23, 2007), http://camr-rcam.hcsc.gc.ca/review-reviser/camr_rcam_janssen_ortho_09-eng.pdf [hereinafter Janssen-Ortho, Inc. Letter].

107 Canadian HIV/AIDS Legal Network, supra note 3, at 5.

108 Id.

109 Government of Canada, supra note 27, at 28-29.

110 Consumer Project on Technology, Legislation to Allow for the Export of Pharmaceuticals Produced Under Compulsory License, http://www.cptech.org/ip/health/cl/cl-export-legislation.html (last visited October 30, 2008).

111 Id.

112 Parliament and Council Regulation 816/2006, 2006 O.J. (L 157/1), available at http://eur-lex.europa.eu/LexUriServ/site/en/oj/2006/l_157/l_15720060609en00010007.pdf.

113 Id. at art. 9.

114 Id. at art. 10.

115 CAMR, supra note 58, at § 21.09.

116 Canadian HIV/AIDS Legal Network, supra note 3, at 5.

117 Id.

118 Id.

119 Government of Canada, supra note 27, at 17.

120 Id.

121 Canadian HIV/AIDS Legal Network, supra note 3, at 5.

122 TRIPS, supra note 12, at art. 31(b).

123 Elliot, , Pledges and Pitfalls: Canada's Legislation on Compulsory Licensing of Pharmaceuticals for Export, 1 Int’l J. Intellectual Prop. Mgmt. 94, 99 (2006)CrossRefGoogle Scholar.

124 Canadian HIV/AIDS Legal Network, supra note 3, at 5-6.

125 Id.

126 Id.

127 Elliot, Pledges and Pitfalls, supra note 123, at 100.

128 Elliot, Delivery Past Due, supra note 88, at 9.

129 Cohen-Kohler, Esmail & Corsio, supra note 29, at 6.

130 The Good Faith Clause limits the amount a generic manufacturer can charge for medications made under a CAMR compulsory license. The price of these drugs must be less than twenty-five percent of the cost of the patented medication in Canada. Id.

131 Id.

132 Apotex Letter, supra note 104, at 2.

133 Id.

134 Canadian HIV/AIDS Legal Network, supra note 3, at 4.

135 Id.

136 Canadian Generic Pharmaceutical Association, Canada's Access to Medicines Regime Consultation Paper 1 (2007), http://camr-rcam.hc-sc.gc.ca/reviewreviser/camr_rcam_cgpa_01_e.pdf.

137 CAMR, supra note 58, at sched. 1.

138 Canadian HIV/Aids Legal Network, supra note 3, at 4.

139 Cohen-Kohler, Esmail & Cosio, supra note 29, at 5.

140 Canadian HIV/AIDS Legal Network, supra note 3, at 4.

141 The Human Rights Working Group on HIV/AIDS and Public Health, supra note 102, at 5.

142 Id.

143 Elliot, Pledges and Pitfalls, supra note 123, at 101.

144 Id.

145 See The North South Institute, Access to Medicines and Intellectual Property: An International Expert Meeting on Canada's Access to Medicines Regime, Global Developments, and New Strategies for Improving Access 36 (2007)Google Scholar.

146 Janssen-Ortho, Inc. Letter, supra note 106, at 1-2.

147 Government of Canada, supra note 27, at 10.

148 The North South Institute, supra note 145, at 36-37.

149 Canadian HIV/AIDS Legal Network, supra note 3, at 4.

150 Elliot, Pledges and Pitfalls, supra note 123, at 101.

151 Id.

152 Id.

153 Id.

154 Id.

155 Canadian HIV/AIDS Legal Network, supra note 3, at 4.

156 Letter from Doug Grant, Vice-President, Corporate Affairs, Bayer Inc. to Brigitte Zirger, Dir. – Therapeutic Product Directorate, Health Can. (Jan. 24, 2007), http://camrrcam.hc-sc.gc.ca/review-reviser/camr_rcam_bayer_16-eng.pdf.

157 Id. at 1-2.

158 Canadian Generic Pharmaceutical Association, supra note 136, at 1.

159 The Human Rights Working Group on HIV/AIDS and Public Health, supra note 102, at 5.

160 Government of Canada, supra note 27, at 10.

161 Id.

162 Id.

163 Apotex Letter, supra note 104, at 2.

164 Government of Canada, supra note 27, at 11.

165 Id.

166 Id.

167 Cohen-Kohler, Esmail & Cosio, supra note 29, at 4.

168 Id.

169 Id.

170 Canadian HIV/AIDS Legal Network, supra note 3, at 4.

171 Id.

172 Id.

173 Elliot, Delivery Past Due, supra note 88, at 5.

174 Id. at 8.

175 Id.

176 Canadian HIV/AIDS Legal Network, supra note 3, at 4.

177 Id.

178 Elliot, Delivery Past Due, supra note 88, at 7.

179 Id.

180 The Human Rights Working Group on HIV/AIDS and Public Health, supra note 102, at 4.

181 The North South Institute, supra note 145, at 35.

182 TRIPS, supra note 12, at art. 31(c).

183 CAMR, supra note 58, at § 21.09.

184 The North South Institute, supra note 145, at 35.

185 Canadian HIV/AIDS Legal Network, supra note 3, at 5.

186 The North South Institute, supra note 145, at 35.

187 Id.

188 Id.

189 Id.

190 Cohen-Kohler, Esmail & Cosio, supra note 29, at 5.

191 Id. at 5, 11-13.

192 Canadian Generic Pharmaceutical Association, supra note 136, at 1.

193 Id. (citing Medecins Sans Frontieres, Neither Expeditious Nor a Solution: The WTO August 30 Declaration Is Unworkable (2006), http://www.msf.ch/fileadmin/user_upload/uploads/communiques/images_2006/pdf/came_Neither_expeditious_nor_a_solution_-_August_30_and_the_JCPA_single_page.pdf).

194 Canadian Generic Pharmaceutical Association, supra note 136, at 1.

195 Cohen-Kohler, Esmail & Cosio, supra note 29, at 5.

196 Id.

197 Id. at 9.

198 Stephen Lewis, Statement by Stephen Lewis, the UN-Secretary-General's Special Envoy for HIV/AIDS, Sep. 25, 2003, http://www.cptech.org/ip/health/c/canada/lewis09252003.html.

199 Elliot, Delivery Past Due, supra note 88, at 6.

200 Cohen-Kohler, Esmail & Cosio, supra note 29, at 5.

201 The Human Rights Working Group on HIV/AIDS and Public Health, supra note 102, at 3.

202 Cohen-Kohler, Esmail & Cosio, supra note 29, at 5.

203 Canadian Generic Pharmaceutical Association, supra note 136, at 1.

204 TRIPS, supra note 12, at art. 31(c).

205 Cohen-Kohler, Esmail & Cosio, supra note 29, at 6-7.

206 Pearson Peace Keeping Center - Our Roots, http://www.peaceoperations.org/web/la/en/pa/A20EB5D052514C04BE3968CA3C161941/template.asp (last visited Nov. 1, 2008).

207 Veterans Affairs Canada - The Capture of Vimy Ridge, http://www.vacacc.gc.ca/remembers/sub.cfm?source=history/firstwar/vimy/vimy5 (last visited Nov. 1, 2008).

208 Robin Rowland, D-Day: Canada's Role, Cbc News, Jun. 5, 2003, http://www.cbc.ca/news/dday/.

209 Government of New Brunswick - John Peters Humphrey, Main Author of the Universal Declaration, http://www.gnb.ca/hrc%2Dcdp/humphrey%2De.asp (last visited, Nov. 1, 2008).

210 Posting of Kelly McMillan to Center for Intellectual Property Policy (June 9, 2008), http://www.cipp.mcgill.ca/blog/category/access-to-medicines/.